Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation
收藏DataCite Commons2025-10-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007913/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Patients with active Axial Spondyloarthritis without x-ray evidence of Ankylosing Spondylitis
and with signs of inflammation will be randomly assigned to receive certolizumab pegol (CZP)
200 mg every two weeks or placebo. The primary objective is to demonstrate the efficacy of
CZP in these patients.
提供机构：
Vivli
创建时间：
2022-06-17
